Versameb Strengthens its Board of Directors
Significant appointments of experienced drug development and financial experts – Hernán Levett, Dr Lily Geidelberg, Paul Korner, MD, MBA and Dr Alexandre LeBeaut...
News
Cellestia Biotech announces the Initiation of Phase II Trial for the treatment of rr/r-T-ALL patients is now open for recruitment
The Investigator Initiated Phase II Trial at MD Anderson Cancer Center combining CB-103 and Venetoclax for the treatment of rr/r-T-ALL patients is now open for recruitment...
BioVersys announces first patient dosed in Phase 2a clinical trial with BVL-GSK098
31.01.2023
BioVersys AG announces first patient dosed in Phase 2a clinical trial with BVL-GSK099, to investigate a new treatment concept to address multidrug-resistance tuberculosis...
BioVersys extends its series C round to CHF 32.6 Million
05.01.2023
BioVersys AG announces extension of its Series C investment round to CHF 32.6 million as the AMR Action Fund makes its first European-based investment...
New Tech Park Basel CEO selected
26.10.2022
We are pleased to announce that Christian Harr (current COO) will become the new CEO of Tech Park Basel. He will take up the new position on...